156 related articles for article (PubMed ID: 28674898)
1. Shotgun and Targeted Plasma Proteomics to Predict Prognosis of Non-Small Cell Lung Cancer.
Li QR; Liu YS; Zeng R
Methods Mol Biol; 2017; 1619():385-394. PubMed ID: 28674898
[TBL] [Abstract][Full Text] [Related]
2. Integrative proteomics and tissue microarray profiling indicate the association between overexpressed serum proteins and non-small cell lung cancer.
Liu Y; Luo X; Hu H; Wang R; Sun Y; Zeng R; Chen H
PLoS One; 2012; 7(12):e51748. PubMed ID: 23284758
[TBL] [Abstract][Full Text] [Related]
3. Verification of the biomarker candidates for non-small-cell lung cancer using a targeted proteomics approach.
Kim YJ; Sertamo K; Pierrard MA; Mesmin C; Kim SY; Schlesser M; Berchem G; Domon B
J Proteome Res; 2015 Mar; 14(3):1412-9. PubMed ID: 25597550
[TBL] [Abstract][Full Text] [Related]
4. Application of proteomics in non-small-cell lung cancer.
Cho WC
Expert Rev Proteomics; 2016; 13(1):1-4. PubMed ID: 26577456
[TBL] [Abstract][Full Text] [Related]
5. Unlocking biomarker discovery: large scale application of aptamer proteomic technology for early detection of lung cancer.
Ostroff RM; Bigbee WL; Franklin W; Gold L; Mehan M; Miller YE; Pass HI; Rom WN; Siegfried JM; Stewart A; Walker JJ; Weissfeld JL; Williams S; Zichi D; Brody EN
PLoS One; 2010 Dec; 5(12):e15003. PubMed ID: 21170350
[TBL] [Abstract][Full Text] [Related]
6. Evaluation of reverse phase protein array (RPPA)-based pathway-activation profiling in 84 non-small cell lung cancer (NSCLC) cell lines as platform for cancer proteomics and biomarker discovery.
Ummanni R; Mannsperger HA; Sonntag J; Oswald M; Sharma AK; König R; Korf U
Biochim Biophys Acta; 2014 May; 1844(5):950-9. PubMed ID: 24361481
[TBL] [Abstract][Full Text] [Related]
7. Quantitative Secretomic Analysis Identifies Extracellular Protein Factors That Modulate the Metastatic Phenotype of Non-Small Cell Lung Cancer.
Hu R; Huffman KE; Chu M; Zhang Y; Minna JD; Yu Y
J Proteome Res; 2016 Feb; 15(2):477-86. PubMed ID: 26736068
[TBL] [Abstract][Full Text] [Related]
8. Proteome analysis of non-small cell lung cancer cell line secretomes and patient sputum reveals biofluid biomarker candidates for cisplatin response prediction.
Böttger F; Schaaij-Visser TB; de Reus I; Piersma SR; Pham TV; Nagel R; Brakenhoff RH; Thunnissen E; Smit EF; Jimenez CR
J Proteomics; 2019 Mar; 196():106-119. PubMed ID: 30710758
[TBL] [Abstract][Full Text] [Related]
9. Comparative proteome analysis across non-small cell lung cancer cell lines.
Grundner-Culemann K; Dybowski JN; Klammer M; Tebbe A; Schaab C; Daub H
J Proteomics; 2016 Jan; 130():1-10. PubMed ID: 26361996
[TBL] [Abstract][Full Text] [Related]
10. Plasma Biomarker Identification and Quantification by Microparticle Proteomics.
Harel M; Geiger T
Methods Mol Biol; 2017; 1619():477-486. PubMed ID: 28674905
[TBL] [Abstract][Full Text] [Related]
11. Qualification and Verification of Serological Biomarker Candidates for Lung Adenocarcinoma by Targeted Mass Spectrometry.
Wu HY; Goan YG; Chang YH; Yang YF; Chang HJ; Cheng PN; Wu CC; Zgoda VG; Chen YJ; Liao PC
J Proteome Res; 2015 Aug; 14(8):3039-50. PubMed ID: 26120931
[TBL] [Abstract][Full Text] [Related]
12. Mass Spectrometry-Based Serum Proteomics for Biomarker Discovery and Validation.
Bhosale SD; Moulder R; Kouvonen P; Lahesmaa R; Goodlett DR
Methods Mol Biol; 2017; 1619():451-466. PubMed ID: 28674903
[TBL] [Abstract][Full Text] [Related]
13. Early Candidate Biomarkers of Non-Small Cell Lung Cancer Are Screened and Identified in Premalignant Lung Lesions.
Nan Y; Du J; Ma L; Jiang H; Jin F; Yang S
Technol Cancer Res Treat; 2017 Feb; 16(1):66-74. PubMed ID: 26809240
[TBL] [Abstract][Full Text] [Related]
14. Identification of GlcNAcylated alpha-1-antichymotrypsin as an early biomarker in human non-small-cell lung cancer by quantitative proteomic analysis with two lectins.
Jin Y; Wang J; Ye X; Su Y; Yu G; Yang Q; Liu W; Yu W; Cai J; Chen X; Liang Y; Chen Y; Wong BH; Fu X; Sun H
Br J Cancer; 2016 Mar; 114(5):532-44. PubMed ID: 26908325
[TBL] [Abstract][Full Text] [Related]
15. Proteomics biomarkers for non-small cell lung cancer.
Kisluk J; Ciborowski M; Niemira M; Kretowski A; Niklinski J
J Pharm Biomed Anal; 2014 Dec; 101():40-9. PubMed ID: 25175018
[TBL] [Abstract][Full Text] [Related]
16. Comparative proteomic analysis of non-small-cell lung cancer and normal controls using serum label-free quantitative shotgun technology.
Pan J; Chen HQ; Sun YH; Zhang JH; Luo XY
Lung; 2008; 186(4):255-261. PubMed ID: 18465169
[TBL] [Abstract][Full Text] [Related]
17. Assessment of SRM, MRM(3) , and DIA for the targeted analysis of phosphorylation dynamics in non-small cell lung cancer.
Schmidlin T; Garrigues L; Lane CS; Mulder TC; van Doorn S; Post H; de Graaf EL; Lemeer S; Heck AJ; Altelaar AF
Proteomics; 2016 Aug; 16(15-16):2193-205. PubMed ID: 27219855
[TBL] [Abstract][Full Text] [Related]
18. Proteomic-Based Approaches for the Study of Cytokines in Lung Cancer.
Marrugal Á; Ojeda L; Paz-Ares L; Molina-Pinelo S; Ferrer I
Dis Markers; 2016; 2016():2138627. PubMed ID: 27445423
[TBL] [Abstract][Full Text] [Related]
19. Protocol for Standardizing High-to-Moderate Abundance Protein Biomarker Assessments Through an MRM-with-Standard-Peptides Quantitative Approach.
Percy AJ; Yang J; Chambers AG; Mohammed Y; Miliotis T; Borchers CH
Adv Exp Med Biol; 2016; 919():515-530. PubMed ID: 27975233
[TBL] [Abstract][Full Text] [Related]
20. Phosphoproteins in extracellular vesicles as candidate markers for breast cancer.
Chen IH; Xue L; Hsu CC; Paez JS; Pan L; Andaluz H; Wendt MK; Iliuk AB; Zhu JK; Tao WA
Proc Natl Acad Sci U S A; 2017 Mar; 114(12):3175-3180. PubMed ID: 28270605
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
